The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients

I Bieche, B Parfait, C Nogues, C Andrieu, D Vidaud, F Spyratos, R Lidereau, M Vidaud

Research output: Contribution to journalArticle (Academic Journal)peer-review

17 Citations (Scopus)

Abstract

We recently identified CGA (coding for the alpha subunit of glycoprotein hormones) as a new estrogen receptor alpha (ER alpha)-responsive gene in human breast tumors. Here, we assessed the relationship between CGA status (as determined by real-time quantitative RT-PCR) and the response to tamoxifen therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal breast cancer patients treated with primary surgery followed by adjuvant tamoxifen alone. CGA overexpression, observed in 37.6% of patients, was associated with good relapse-free survival (P=0.037; univariate analysis). CGA status, combined with ERBB2 status (a marker of poor outcome), was an independent predictor of the response to tamoxifen (P=0.020; multivariate analysis). CGA status, especially when combined with ERBB2 status, may thus provide useful predictive information on tamoxifen responsiveness in breast cancer.
Translated title of the contributionThe CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients
Original languageEnglish
Pages (from-to)6955 - 6959
JournalOncogene
Volume20 (47)
Publication statusPublished - Oct 2001

Bibliographical note

Publisher: Nature Publishing Group
Other identifier: IDS Number: 483NK

Fingerprint Dive into the research topics of 'The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients'. Together they form a unique fingerprint.

Cite this